Development of a novel celecoxib-loaded nanosuspension using a wet media milling process

Pharmazie. 2018 Sep 1;73(9):498-502. doi: 10.1691/ph.2018.8035.

Abstract

To develop a novel celecoxib (CXB)-loaded drug delivery system, numerous nanosuspensions were prepared with various polymers and surfactants using a wet media milling process, and their particle sizes were subsequently determined. A 24 full factorial design was used to identify the most appropriate preparation conditions. Pharmacokinetics of the selected nanosuspension were performed in rats and compared with those of a drug powder and a commercial CXB-loaded product. Among the carriers investigated, copovidone and sodium lauryl sulphate gave the smallest particle size of the drug in the nanosuspension. In particular, the nanosuspension prepared with 5% CXB, 4% copovidone, and 0.1% sodium lauryl sulphate, under the appropriate conditions, showed a particle size of approximately 190 nm, which was physically stable for at least 8 weeks. This nanosuspension provided a significantly higher plasma concentration and AUC in rats as compared with the drug powder and the commercial product. Thus, this novel CXB-loaded nanosuspension is a promising candidate with excellent stability and enhanced oral bioavailability.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Area Under Curve
  • Biological Availability
  • Celecoxib / administration & dosage*
  • Celecoxib / chemistry
  • Celecoxib / pharmacokinetics
  • Chemistry, Pharmaceutical / methods
  • Cyclooxygenase 2 Inhibitors / administration & dosage*
  • Cyclooxygenase 2 Inhibitors / chemistry
  • Cyclooxygenase 2 Inhibitors / pharmacokinetics
  • Drug Delivery Systems*
  • Drug Stability
  • Male
  • Nanoparticles*
  • Particle Size
  • Polymers / chemistry
  • Powders
  • Rats
  • Rats, Sprague-Dawley
  • Surface-Active Agents / chemistry
  • Suspensions

Substances

  • Cyclooxygenase 2 Inhibitors
  • Polymers
  • Powders
  • Surface-Active Agents
  • Suspensions
  • Celecoxib